Background. In recent years, urinary tract infections (UTIs) due to extendedspectrum β-lactamase (ESBL)-producing gram-negative bacilli show an increased incidence both among out-patients and hospitalized group of patients in our country as well as around the world. Because of the ESBL-producing bacterial infections, patients' hospitalization, morbidity and mortality rates increase and this condition causes an increasing cost of treatment and socio-economic losses. The primary outcome of this study was to evaluate the cost of treatment with ertapenem for the treatment of UTIs due to ESBL-producing gram-negative bacilli in hospitalized patients and to calculate the estimated difference regarding costs between outpatients and hospitalized patients. Use of ertapenem in an OPAT programme is not available in our country. The secondary outcome was to assess whether ertapenem was suitable for outpatient paranteral antibiotic therapy (OPAT) programme in Turkey in future.
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Methods. A total of 53 patients hospitalized between 2008 and 2010 with the diagnosis of UTI caused by ESBL-producing gram-negative bacilli and treated with ertapenem were retrospectively evaluated. The cost of ertapenem treatment as inpatient antibiotic therapy (IPAT) was calculated regarding hospital records. The estimated cost of the same antibiotic for the same patients as an OPAT programme was then calculated and the costs were compared.
Results. Ertapenem therapy was found to be safe and effective and its implementation as an OPAT programme would provide an estimated 20% reduction in projected costs. Consequently, the estimated patient bed days gained was calculated as 583 days, which constitutes about 5% of the total number of hospitalization days.
Conclusion. In our country, applying ertapenem therapy for UTIs due to ESBLproducing gram-negative bacilli, where the incidence is increasing each year, through OPAT programme will decrease the financial burden of health expenses. Also, this programme will reduce the number of inpatient bed days required for successful treatment and increase patient satisfaction.
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